RIPK3 and rheumatoid arthritis: This process can be mitigated by downregulating RIPK3 or administering necrostatin‐1.[166] In addition, studies have indicated that, in the joints of patients with rheumatoid arthritis, neutrophils activate RIPK1, RIPK3, and MLKL under the influence of CD44 and GM‐CSF, leading to necroptosis,[167] thereby exacerbating tissue damage.